Stock Ratings / Health Care / PPBT / insiders

KAPA (37) MTNB (35) OGEN (44) XRTX (46) ⌘ Pro Terminal →

Purple Biotech Ltd. (PPBT) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$1.09 +13.86% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.12

Purple Biotech Ltd. (PPBT) carries a Roarable Rating of C- (Hold) with 61/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 61/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.5% avg 90D alpha vs SPY) →

ROARABLE C- • HOLD / WATCH Cap $1.8M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PPBT Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is PPBT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Purple Biotech Ltd. (NASDAQ: PPBT) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 61/100 at a spot price of $1.09 (+13.86% 1D, market cap $1.8M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, PPBT ranks #171 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does PPBT compare to KAPA and MTNB in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PPBT carries a Roarable C- (61/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, KAPA (Kairos Pharma Ltd.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $1.8M) and MTNB (Matinas Biopharma Holdings Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $1.9M). Among the 5-stock peer group, PPBT leads on earnings multiple (N/A) while KAPA leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PPBT?

▼

For Purple Biotech Ltd. (PPBT), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #171 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.12 (+2.30%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 61/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.5% avg 90D alpha vs SPY • 53.9% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C-

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE+0.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PPBT)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (61/100 Composite)

🔍 WHY PPBT SCORES 61/100 (C-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+14/20 pts (23% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (21% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution9/20 pts (-11 pt drag)

Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade B-$1.33-14.3% Next Q

Q2 (-2Q)

Grade B-$1.14-5.3% Next Q

Q3 (-1Q)

Grade C+$1.08+0.9% Next Q

Current

Grade C-$1.09+0.5% Hist 90D α

Trajectory: B- (69) → C- (61)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the PPBT Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 61/100 (C-) score, PPBT faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Disciplined Float (-0.40% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($1.46) or 200D SMA ($3.02) invalidates the momentum regime and cuts Target Base ($1.10) toward Bear Floor ($0.86).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PPBT• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “PPBT Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”

YES 61%NO 39%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

PPBT Smart-Money Thermometer: BALANCED INSTITUTIONAL POSITIONING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (PPBT)

No recent open-market Form 4 cluster sales or emergency dumps flagged on PPBT. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (PPBT Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

PPBT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -73.61%🛡️ HOLDING TREND SUPPORT

2026-10-30O $1.09H $1.17L $1.07C $1.09VOL 41.6K

RES: $3.26SUP: $0.88SMA50: $1.46SMA200: $3.02

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PPBT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PPBT Butterfly Map → + Track PPBT →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on PPBT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PPBT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for PPBT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PPBT)

Health Care Rank #171 of 1016 ⚔️ KAPA vs PPBT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PPBT vs. KAPA, MTNB, OGEN, XRTX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Purple Biotech Ltd. (PPBT) ranks #171 by composite RQD confidence (61/100, grade C-) and #1005 by equity capitalization ($1.8M). Within this direct 5-issuer industry benchmark cohort, PPBT leads on earnings valuation at N/A trailing P/E, while KAPA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. PPBT currently leads its immediate peer cohort in composite quantitative strength at 61/100 (C-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
PPBT ACTIVE Purple Biotech Ltd.	C-	61/100	—	—	—	+13.86%	$1.8M	Benchmark Subject
KAPA Kairos Pharma Ltd.	D-	37/100	—	—	-35.0%	+3.25%	$1.8M	/kapa-vs-ppbt →
MTNB Matinas Biopharma Holdings Inc.	D-	35/100	—	—	-35.0%	-0.52%	$1.9M	/mtnb-vs-ppbt →
OGEN Oragenics Inc.	D	44/100	—	—	-35.0%	-1.53%	$1.7M	/ogen-vs-ppbt →
XRTX XORTX Therapeutics Inc.	D	46/100	—	—	—	-1.90%	$1.9M	/xrtx-vs-ppbt →

2. PPBT Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Purple Biotech Ltd. (PPBT) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $1.8M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. PPBT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PPBT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does PPBT compare to KAPA and MTNB in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for PPBT?

Where is PPBT trading relative to its 50-day, 200-day, and 52-week technical levels?

PPBT last traded at $1.09 (+13.86% on volume of 33,690 shares), positioning the stock -25.34% below its 50-day simple moving average ($1.46) and -63.91% below its 200-day simple moving average ($3.02). Across its 52-week range of $0.91 to $9.10, PPBT sits at the 2.2% percentile with a 14-day RSI of 45.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.23).

PPBT Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are PPBT insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies PPBT leadership and institutional positioning as: BALANCED INSTITUTIONAL POSITIONING.

Direct Sub-Reports: PPBT RQD Cockpit PPBT 12M Forecast PPBT Earnings & Move PPBT Dividends & DRIP PPBT Insiders & 13F PPBT Whale Options PPBT Profit Sankey PPBT News & Why